Comparison of the Human Acellular Vessel (HAV) With ePTFE Grafts as Conduits for Hemodialysis
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 355 participants.
Also called NCT02644941
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 355 participants
- Registry
-
NCT02644941 -
2015-003261-28
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Germany, Israel, Poland, Portugal, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT02644941. Randomized; no masking; primary purpose treatment. Start 2016-05-24 (actual); primary completion 2019-05 (actual). Results posted on 2025-03-30.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Comparison of the Human Acellular Vessel (HAV) With ePTFE Grafts as Conduits for Hemodialysis
- Condition
- Renal Failure
- Condition
- End Stage Renal Disease
- Condition
- Hemodialysis
- Condition
- Vascular Access
- Intervention (Biological)
- Human Acellular Vessel (HAV)
- Intervention (Device)
- ePTFE graft
- Lead sponsor
- Humacyte, Inc.
- Collaborator
- CTI Clinical Trial and Consulting Services
- Collaborator
- California Institute for Regenerative Medicine (CIRM)
Record details
- Record id
cardio:ct-nct02644941- Content hash
ac56f1859191cdd2519ad625c38dd12646751085d706d2e9ce100b5b9341b3f0